GLP-1 Side Effects: From Digestive Issues to Muscle Loss

Nausea and other digestive complaints are by far the most common side effects of GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide, and they are the leading reason people stop taking these drugs. But the side-effect profile extends well beyond an upset stomach. Depending on the individual, GLP-1 medications can affect muscle mass, gallbladder health, heart rate, nutrient absorption, and even facial appearance. Some of these effects are well-established; others are still being sorted out in the research.

Digestive Side Effects Are the Headliner

If you take a GLP-1 receptor agonist, there is a good chance you will experience some gastrointestinal discomfort, at least initially. Nausea, vomiting, diarrhea, and constipation are the most frequently reported problems. A multidisciplinary expert consensus on managing these effects found that a careful, gradual dose escalation is the primary strategy for keeping them tolerable, and that specific dietary adjustments during the ramp-up period can reduce their severity and duration.¹ These symptoms are not random. GLP-1 receptors are present throughout the nervous system controlling the gut, and activating them directly slows the muscular contractions that move food through the stomach and intestines.²

For most people, the nausea fades as the body adjusts over a few weeks. But for a meaningful fraction, it does not. Real-world data show that between 20% and 50% of patients stop GLP-1 medications within the first year, and the most commonly cited reasons are digestive problems and cost.³ In one cross-sectional survey of patients who had discontinued a GLP-1 drug, roughly two-thirds reported “it made me feel sick” as a top reason, and about 45% said vomiting specifically drove their decision to stop.⁴ That dropout rate matters for everything else discussed in this article, because most side effects are manageable if you can stay on the medication long enough for the benefit to accumulate.

Gastroparesis and Other Serious GI Complications

Beyond everyday nausea, GLP-1 drugs carry a small but real risk of more severe gastrointestinal problems. A large study published in JAMA compared GLP-1 agonists to the weight-loss drug bupropion-naltrexone and found that GLP-1 use was associated with a roughly ninefold increase in the rate of pancreatitis and about a fourfold increase in gastroparesis, which is a condition where the stomach empties abnormally slowly.⁵ A separate retrospective study specifically looking at semaglutide found a gastroparesis rate of about 6.5 per 1,000 person-years, compared with roughly 2 per 1,000 among bupropion-naltrexone users, translating to about triple the risk after adjusting for patient differences.⁶

The JAMA study also flagged an elevated risk of bowel obstruction. However, a large Scandinavian cohort study covering more than 120,000 new GLP-1 users found no statistically significant increase in intestinal obstruction compared with users of another diabetes drug class, with adjusted event rates of 1.3 versus 1.6 per 1,000 person-years.⁷ The contradiction likely comes down to study design and comparator choice. In absolute terms, these severe gastrointestinal events remain uncommon, but they are worth being aware of, especially if you already have slow digestion or a history of gut motility problems.

Gallbladder and Pancreas Risks

Gallstones and gallbladder inflammation get their own discussion because the evidence here is fairly robust. A systematic review and meta-analysis of 76 randomized controlled trials found that people taking GLP-1 drugs had a 37% higher risk of gallbladder or biliary disease overall, including higher rates of gallstones and gallbladder inflammation specifically.⁸ The risk was more than doubled in trials where GLP-1 drugs were used for weight loss specifically, compared with trials focused on diabetes management. Higher doses and longer treatment periods both pushed the risk upward.⁹ This makes sense biologically: rapid weight loss by any means increases the risk of gallstones, and GLP-1 drugs at weight-loss doses promote faster fat reduction than at diabetes-treatment doses.

The pancreatitis picture is more nuanced. A meta-analysis of randomized controlled trials found a statistically significant 44% increased risk of pancreatitis with GLP-1 drugs overall, though the signal weakened and lost significance when the researchers stratified by whether patients were also taking other diabetes medications.¹⁰ An interesting target trial emulation study added a wrinkle: it found that while GLP-1 drugs were associated with a higher rate of drug-induced pancreatitis, they were simultaneously associated with lower rates of pancreatitis caused by high triglycerides and alcohol, leaving the overall all-cause pancreatitis rate roughly unchanged compared with sulfonylureas.¹¹ In other words, the drug may slightly increase one type of pancreatic inflammation while reducing others, partly because it improves the metabolic factors that cause pancreatitis in the first place.

Muscle Loss and Body Composition

When you lose weight on a GLP-1 drug, not all of what you lose is fat. Studies show that roughly 25% to 40% of the weight lost consists of lean mass, meaning muscle and other non-fat tissue.¹² That ratio is not unique to these drugs; it is roughly what happens with any significant calorie restriction. A recent analysis pointed out that calorie-cutting diets produce a similar proportion of lean mass loss, and framing the muscle loss as a GLP-1-specific problem overstates things.¹³

Still, the concern is real for certain groups. Older adults, people who were already carrying low muscle mass before starting treatment, and those with conditions that accelerate muscle wasting are at heightened risk of tipping into sarcopenia, a state where muscle loss starts to impair daily functioning.¹⁴ A scoping review of GLP-1 use in older adults noted that while evidence on physical performance outcomes remains limited, muscle mass loss during treatment is common enough to warrant routine monitoring, and weight cycling on and off the drugs adds further uncertainty about long-term skeletal muscle health.¹⁵ Resistance exercise and adequate protein intake are the standard recommendations for protecting muscle mass during any weight-loss program, but dedicated studies in GLP-1 users with sarcopenia risk are still lacking.

Nutritional Deficiencies

The same appetite suppression and slowed digestion that produce weight loss can also reduce how much nutrition you absorb. A retrospective study of adults with type 2 diabetes found that about 13% developed a nutritional deficiency within six months of starting a GLP-1 drug, and that figure climbed to roughly 22% by one year. Vitamin D deficiency was the most common, affecting about 14% at 12 months.¹⁶

A narrative review looking more broadly at micronutrient status in GLP-1 users found the problem extends beyond vitamin D. Iron depletion was common, with GLP-1 users showing ferritin levels about a quarter to a third lower than people on a different diabetes drug class. More than 60% of users consumed below estimated requirements for calcium and iron, and average vitamin D intake sat at just 20% of recommended levels. Thiamine and vitamin B12 deficits also appeared to worsen over time on treatment.¹⁷ The mechanism is straightforward: eat substantially less food, absorb substantially fewer nutrients. This is another reason why simply taking the medication without attention to diet quality can backfire, and it connects directly to the muscle-loss concern, since inadequate protein and calcium both accelerate lean mass decline.

Heart Rate Increases

GLP-1 drugs raise resting heart rate, and this effect varies across the class. A review of heart rate data found that long-acting GLP-1 drugs like liraglutide and albiglutide produced the largest increases, on the order of 6 to 10 beats per minute, while dulaglutide and extended-release exenatide raised heart rate by about 3 to 4 beats per minute. Short-acting versions caused a smaller, more transient increase that tended to return to baseline.¹⁸ A study of heart failure patients with implanted cardiac devices found that GLP-1 drug initiation raised heart rate by about 7 beats per minute on average after adjustment.¹⁹

Research suggests GLP-1 acts directly on the sinus node, the heart’s natural pacemaker, rather than increasing heart rate only through nervous system pathways.²⁰ For most people, a few extra beats per minute is not clinically meaningful, especially since large cardiovascular outcome trials have consistently shown that GLP-1 drugs reduce rates of heart attack and stroke overall. But in people with certain arrhythmias or severe heart failure, even a modest persistent heart rate increase deserves monitoring.

The Suicidality Signal

After GLP-1 drugs became widely prescribed, reports surfaced in pharmacovigilance databases suggesting a possible link to suicidal thoughts. An analysis of the FDA’s adverse event reporting system found disproportionate reporting of suicidal ideation for semaglutide and liraglutide specifically, though reports of actual suicide attempts and completed suicides were not elevated for any approved GLP-1 drug.²¹

A replication study using the World Health Organization’s global pharmacovigilance database showed a more complex picture. Reporting odds for suicidal ideation and depressive symptoms were elevated for semaglutide, liraglutide, and tirzepatide. But for suicide attempts, the odds were actually significantly lower for semaglutide, liraglutide, dulaglutide, and exenatide compared with other drugs. The same pattern held for completed suicides, where GLP-1 users were dramatically underrepresented.²² This creates an odd split: more reports of suicidal thoughts, fewer reports of suicidal actions. One interpretation is that people taking highly publicized drugs are more likely to report psychological symptoms to their doctors, while the drugs themselves may actually be protective through improvements in metabolic health, inflammation, or quality of life. Regulatory agencies have investigated and not added suicide warnings to these drugs, but monitoring continues.

Facial Volume Loss and Skin Changes

The phenomenon casually called “Ozempic face” refers to the gaunt, aged appearance that some people develop after rapid weight loss on GLP-1 medications. The face loses fat from the cheeks, temples, jawline, and around the eyes, making skin sag and making wrinkles and folds more prominent.²³ A dermatological review described the underlying process as a temporal mismatch: fat disappears faster than the skin and connective tissue can tighten to accommodate the new contour, producing a draped, hollow look that reads as accelerated aging.²⁴

Evidence that GLP-1 drugs specifically target facial fat is lacking. The more likely explanation is that the face simply has less fat to begin with, so even a proportional loss across the whole body shows up disproportionately in the face, especially in older people whose collagen levels are already declining. Researchers are investigating whether modulating specific cellular receptors in facial fat tissue could prevent this kind of localized volume loss during treatment, but that work remains early-stage.²⁵ For now, dermal fillers and other cosmetic procedures are the main approach for people who find the facial changes distressing.

What Happens Under Anesthesia

Because GLP-1 drugs slow gastric emptying, they create a specific concern for anyone undergoing surgery or sedation. A stomach that still contains food hours after what should have been an adequate fasting period raises the risk of aspiration, where stomach contents enter the lungs during anesthesia. A multidisciplinary consensus statement from the Society for Perioperative Assessment and Quality Improvement flagged this as a recognized perioperative concern, supported by multiple case reports and observational studies.²⁶

The practical numbers offer some reassurance. Meta-analyses involving more than 300,000 patients found that while retained stomach contents were substantially more common in GLP-1 users (with odds increased anywhere from several-fold to dramatically depending on the analysis), actual pulmonary aspiration rates remained very low, around 0.1% to 0.2%, with no significant increase compared with control groups.²⁷ In practice, most anesthesiology guidelines now recommend either temporarily stopping GLP-1 drugs before elective surgery or performing a bedside ultrasound of the stomach to check for retained food. If you have a procedure coming up, this is something to discuss with both your prescriber and your surgical team well in advance.

Weight Rebound After Stopping

One of the most talked-about realities of GLP-1 therapy is what happens when you stop. A systematic review with nonlinear modeling found that about 60% of the weight lost during treatment was regained within one year of stopping, and the trajectory was estimated to plateau at roughly 75% regain.²⁸ A separate meta-analysis of randomized controlled trials found that among people with obesity, stopping a GLP-1 drug led to an average weight regain of about 5.6 kilograms, along with increases in blood sugar, blood pressure, and waist circumference. The rebound was larger with semaglutide than with liraglutide and grew more pronounced after longer follow-up.²⁹

The rebound is not limited to weight. Modeling studies suggest that improvements in blood sugar control, blood pressure, and cholesterol all return to pre-treatment levels within about 12 months, with blood sugar markers taking up to 18 months to fully normalize back to where they started.³⁰ This is the strongest argument for viewing these medications as long-term treatments for a chronic condition rather than short-term weight-loss courses. But that framing runs headlong into the dropout rates mentioned earlier: if half of users quit within a year because of side effects or cost, the rebound becomes the most common outcome in practice.

Thyroid Cancer, Hypoglycemia, and Other Flagged Risks

GLP-1 drug labels carry a boxed warning about thyroid C-cell tumors, which has understandably alarmed people. The concern originated from rodent studies where long-term exposure to liraglutide caused thyroid tumors in rats and mice. But there is a clear biological reason this finding may not apply to humans: rodent thyroid cells have GLP-1 receptor densities 22 to 45 times higher than human cells, and monkey thyroid cells showed no proliferative response even at 60 times the maximum recommended human dose. Clinical studies in people with type 2 diabetes have not found increased levels of calcitonin, the hormone that would rise if C-cells were being stimulated to grow.³¹ The warning remains on the label out of an abundance of caution, but the weight of evidence suggests the rodent finding does not translate to human risk.

Hypoglycemia, or dangerously low blood sugar, is rare when a GLP-1 drug is used alone. The risk increases meaningfully when these drugs are combined with insulin or sulfonylureas, which independently lower blood sugar through different mechanisms.³² If you are starting a GLP-1 drug and already take insulin or a sulfonylurea, your doctor will likely need to adjust those doses downward.

Acute kidney injury has also appeared in post-marketing reports, initially linked to the severe dehydration that nausea and vomiting can cause. As more GLP-1 drugs have entered the market, kidney injury cases have continued to surface, and not all can be attributed to dehydration alone, suggesting there may be additional mechanisms at play that are not yet well understood.³³ Staying well hydrated, especially during the early weeks of treatment when nausea peaks, is one of the simplest ways to protect kidney function.

Injection Site Reactions and Immune Responses

Because GLP-1 drugs are injectable proteins, they can provoke local immune responses at the injection site. Rates vary considerably across the drug class. Exenatide carries the highest risk, with injection site reactions reaching 12% to 13% in a meta-analysis, while dulaglutide runs about 1% to 2%, and liraglutide appears to have even lower rates.³⁴ Most reactions are mild and present as redness, swelling, or pain that resolves on its own. Injecting cold medication straight from the refrigerator and failing to rotate injection sites both make reactions more likely.³⁵

True antibody formation against the drug itself is uncommon. Across nine clinical trials, only about 1.6% of dulaglutide-treated patients developed treatment-related antibodies, and those who did showed no meaningful increase in allergic reactions or injection site problems compared with placebo.³⁶ More severe reactions like delayed hypersensitivity or firm nodules at injection sites have been documented but remain rare. Letting the medication reach room temperature before injecting and consistently rotating between different body sites are simple, effective countermeasures for the occasional sore spot.